| Literature DB >> 35873779 |
Di Ma1, Xin Li1, Quan Xu1, Fei Yang1, Yutong Feng1, Wenxu Wang1, Jian-Jia Huang2,3,4, Yu-Cheng Pei2,5,3,4, Yu Pan1.
Abstract
Study Design: A randomized controlled pilot study. Background: Bimanual therapy (BMT) is an effective neurorehabilitation therapy for the upper limb, but its application to the distal upper limb is limited due to methodological difficulties. Therefore, we applied an exoskeleton hand to perform robot-assisted task-oriented bimanual training (RBMT) in patients with stroke. Objective: To characterize the effectiveness of RBMT in patients with hemiplegic stroke with upper limb motor impairment. Interventions: A total of 19 patients with subacute stroke (1-6 months from onset) were randomized and allocated to RBMT and conventional therapy (CT) groups. The RBMT and CT groups received 90 min of training/day (RBMT: 60 min RBMT + 30 min CT; CT: 60 min CT for hand functional training + 30 min regular CT), 5 days/week, for 4 weeks (20 sessions during the experimental period). Assessments: Clinical assessments, including the Fugl-Meyer assessment of the upper extremity (FMA-UE), action research arm test (ARAT), and wolf motor arm function test (WMFT), were conducted before and after the intervention.Entities:
Keywords: exoskeleton; hand function; neurorehabilitation; robot-assisted bimanual task-oriented therapy; stroke
Year: 2022 PMID: 35873779 PMCID: PMC9298653 DOI: 10.3389/fneur.2022.884261
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Figure 1(A) The exoskeleton robotic device and (B) the motor trace of robot-assisted bimanual therapy (RBMT) used in this study; the circle red was the initial point. (C–F) Demonstrated an example of the motor path of a ball gasping/releasing task according to the (B).
Figure 2The CONSORT flowchart.
The summary of participant's characteristics.
|
|
|
|
|
|---|---|---|---|
|
|
| ||
|
| |||
| Male / female | 9/1 | 5/4 | 0.141 |
|
| 59.00 ± 10.60 | 56.44 ± 8.79 | 0.577 |
|
| |||
| Right- / left- side | 4/6 | 5/4 | 0.656 |
|
| |||
| Hemorrhagic / ischemia | 0/10 | 2/7 | 0.211 |
|
| 10.00 ± 5.85 | 10.33 ± 6.24 | 0.906 |
|
| 27.20 ± 17.03 | 22.56 ± 17.17 | 0.562 |
| FMA-SE score | 19.90 ± 9.88 | 15.33 ± 10.61 | 0.983 |
| FMA-WH score | 7.30 ± 8.11 | 7.22 ± 7.36 | 0.345 |
|
| 10.90 ± 10.33 | 12.67 ± 14.37 | 0.760 |
|
| 24.20 ± 14.67 | 23.33 ± 17.80 | 0.909 |
|
| 9.50 ± 8.15 | 10.11 ± 10.06 | 0.886 |
|
| 71.07 ± 34.41 | 79.79 ± 38.80 | 0.610 |
Chi-squared test;
Independent t-test.
Within-group comparisons of clinical assessment scores.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| FMA-UE | 22.56 ± 17.17 | 26.78 ± 18.95* | 30.11 ± 20.95† | 27.20 ± 17.03 | 31.90 ± 17.01* | 36.40 ± 16.87† |
| FMA-SE | 15.33 ± 10.61 | 17.00 ± 11.73 | 18.67 ± 13.33† | 19.90 ± 9.88 | 21.70 ± 9.38 | 23.00 ± 9.35† |
| FMA-WH | 7.22 ± 7.36 | 9.78 ± 7.74 | 11.44 ± 7.86† | 7.30 ± 8.11 | 10.10 ± 7.98* | 13.40 ± 7.73† |
| WMFT-FAS | 23.33 ± 17.80 | 26.33 ± 19.36 | 30.22 ± 20.02 | 24.20 ± 14.67 | 29.80 ± 15.64* | 33.60 ± 16.40† |
| WMFT-FT | 10.11 ± 10.06 | 12.78 ± 11.70 | 15.33 ± 13.27 | 9.50 ± 8.15 | 13.60 ± 9.89* | 16.20 ± 10.92† |
| WMFT-time(s) | 79.79 ± 38.80 | 70.56 ± 45.28* | 64.86 ± 44.47† | 71.07 ± 34.41 | 57.25 ± 39.9* | 53.05 ± 38.89† |
| ARAT | 12.67 ± 14.37 | 16.56 ± 17.33 | 18.44 ± 18.17 | 10.90 ± 10.33 | 15.50 ± 12.60 | 20.00 ± 16.51 |
T.
Significance levels are p < 0.017.
Comparison of intervention effects to the minimal clinically important difference (MCID) in the Fugl–Meyer assessment of the upper extremity (FMA-UE), wolf motor arm function test (WMFT), WMFT-FAS, and action research arm test (ARAT) assessments.
|
| ||||
|---|---|---|---|---|
|
|
|
| ||
| FMA-UE | CT | 9 | 7.56 | 22.22% (2/9) |
| RBMT | 9.20 | 70% (7/10) | ||
| WMFT-FAS | CT | 0.3 | 0.46 | 66.67% (6/9) |
| RBMT | 0.63 | 90.00% (9/10) | ||
| WMFT-time (s) | CT | 9 | 14.93 | 33.33% (3/9) |
| RBMT | 18.02 | 40.00% (4/10) | ||
| ARAT | CT | 12 | 9.10 | 22.22% (2/9) |
| RBMT | 5.78 | 40.00% (4/10) | ||
p < 0.05, Chi-squared test.